WallStreetZenWallStreetZen

NASDAQ: GLUE
Monte Rosa Therapeutics Inc Earnings & Revenue

GLUE earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$132.9M
Current Profit Margin
0%

GLUE Return on Equity

Current Company
-58.2%
Current Industry
15.6%
Current Market
-9.5%
GLUE's Return on Equity (-58.2%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when GLUE announces earnings.

GLUE Return on Assets

Current Company
-45%
Current Industry
2.2%
GLUE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

GLUE Return on Capital Employed

Current Company
-57.75%
Current Industry
17.7%

GLUE vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
GLUE$0.00-$125.46M-$132.88MN/AN/A
XOMA$4.41M-$25.78M-$32.17M-13.24%N/A
INMB$224.00k-$27.43M-$27.43M+177.92%N/A
MACK$0.00-$1.43M-$1.43MN/AN/A
IPHA$56.83M-$16.90M-$68.14M-57.37%N/A

Monte Rosa Therapeutics Earnings & Revenue FAQ

What were GLUE's earnings last quarter?

On Invalid Date, Monte Rosa Therapeutics (NASDAQ: GLUE) reported Q3 2023 earnings per share (EPS) of -$0.70, up 20.69% year over year. Total Monte Rosa Therapeutics earnings for the quarter were -$34.88 million. In the same quarter last year, Monte Rosa Therapeutics's earnings per share (EPS) was -$0.58.

If you're new to stock investing, here's how to buy Monte Rosa Therapeutics stock.

What was GLUE's earnings growth in the past year?

As of Q4 2023, Monte Rosa Therapeutics's earnings has grown year over year. Monte Rosa Therapeutics's earnings in the past year totalled -$132.88 million.

What was GLUE's revenue last quarter?

On Invalid Date, Monte Rosa Therapeutics (NASDAQ: GLUE) reported Q3 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Monte Rosa Therapeutics's revenue was $0.00.

What was GLUE's revenue growth in the past year?

As of Q4 2023, Monte Rosa Therapeutics's revenue has grown null year over year. Monte Rosa Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.